Buying direct from Lilly: Zepbound and Foundayo

Since February 23, 2026, LillyDirect sells every Zepbound dose at a flat self-pay price: $299 for 2.5 mg, $399 for 5 mg, and $449 for everything from 7.5 mg to 15 mg. One month means four single-dose vials or one KwikPen, your choice.[1][4]

The catch is the refill window. You keep those prices only if each refill lands within 45 days of the last one. Let it lapse and the higher doses revert to Lilly's standard self-pay rates of $499 to $699 a month depending on dose. Worth a calendar reminder.[1]

Foundayo works the same way: $149 for the 0.8 mg starter, $199 for 2.5 mg, $299 for 5.5 and 9 mg, and $349 for the top 14.5 and 17.2 mg doses, which drop to $299 if you stay on time under the Self-Pay Journey Program. In trials the top dose averaged about 12.4% weight loss at 72 weeks.[12][11][13]

Savings cards and the insurance reality

If your commercial plan covers the drug, manufacturer savings cards do the heavy lifting: Zepbound as low as $25 a month, Wegovy as low as $0, Foundayo as low as $25.[14][15][12]

One rule people miss: savings cards are for commercial insurance only. If you're on Medicare, Medicaid or TRICARE, you legally can't use them.[14]

Getting covered in the first place is the real fight. Many plans still exclude weight loss drugs outright, and the ones that cover them usually want prior authorization, sometimes step therapy, before they pay. If your plan says no, the direct cash prices above are your fallback, and they're now low enough that plenty of insured people just pay cash.

The list prices you see quoted ($1,086 for Zepbound, $1,349 for Wegovy) are mostly a negotiating anchor at this point. Novo has already announced Wegovy's list price drops to about $675 from January 1, 2027.[2][25]

Where compounded GLP-1s stand

If you got cheap compounded semaglutide or tirzepatide in 2024, that era is over. The FDA declared the tirzepatide shortage resolved in December 2024 and semaglutide in February 2025. Once the wind-down deadlines passed in spring 2025, mass-produced copies became unlawful for compounding pharmacies, and the industry's lawsuits failed to stop it.[19]

In May 2026 the FDA went further and proposed permanently removing semaglutide, tirzepatide and liraglutide from the 503B bulk compounding list, shortage or no shortage. Narrow exceptions survive for genuine individual need, like a documented allergy to an inactive ingredient.[20]

The cautionary tale: Hims & Hers announced a $49 compounded copy of the Wegovy pill in February 2026, pulled it within days under legal and regulatory pressure, and got sued by Novo Nordisk anyway. By March, Novo had dropped the suit as part of a deal that has Hims selling branded Wegovy instead. With branded cash prices at $149 to $449, compounding's price advantage has mostly evaporated anyway.[21]

What's coming next

Retatrutide: not yet approved, still in trials. Lilly's triple agonist posted around 28.3% average weight loss at 80 weeks on the top 12 mg dose in the Phase 3 TRIUMPH-1 trial, reported in May 2026. Those headlines are why people keep asking if it's out. It isn't. It is not approved anywhere, no application had been filed with the FDA as of July 2026, and Lilly's filing is expected around late 2026 or early 2027, which puts realistic approval in late 2027 at the earliest. If you saw news about an approved Lilly weight loss pill, that was Foundayo (orforglipron), a different drug. Anything sold online as retatrutide today is unapproved research-grade material. Don't buy it.[28][24][23]

On price, the direction is down: Wegovy's list price falls to about $675 in January 2027, the Medicare Bridge runs through the end of 2027, and two oral pills now compete with the injections at $149 to $349 cash.[25][16]